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Abstract Activin A, a member of the TGFL superfamily, has
many physiological and developmental functions. In pancreatic
L cell cultures, activin promotes cell differentiation and insulin
production. The author has found activin increases gene
expression of the PAX4, one of the major transcription factors
determining pancreatic L cell differentiation. This effect was
mediated, at least in part, by the type IB activin receptor
(ALK4). Moreover, the activity of human insulin promoter^
reporter system was controlled by PAX4 and its isoform PAX4
v(G239^P251) in a unique fashion; positively by low concentra-
tions, and negatively by high concentrations of these proteins.
And the repression activities were different between these
proteins. These findings confirm the importance of activin signal
transduction in pancreatic L cell development and func-
tion. ß 2000 Federation of European Biochemical Societies.
Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
Gene disruption experiments have revealed that lots of
transcription factors are orchestrally involved in the process
of pancreatic morphogenesis and di¡erentiation in a coordi-
nated manner [1^3]. Initially, HB-9 [4,5], PDX-1 (also desig-
nated as IDX-1, STF-1, IPF-1) [6,7], and ISL-1 [8] have crit-
ical roles in morphogenesis. In addition, Notch signal
mediating molecules including HES-1 and neurogenin-3
(ngn3) regulate cell fate as endocrine or exocrine [9^11]. In
endocrine cells, HNF6 a¡ects cell di¡erentiation by stimula-
tion of ngn3 expression [12]. PAX4 and PAX6 commit to
determine the cell types as K cells or L/N cells [13,14], and
NKX2.2 [15] and BETA2 (also known as NeuroD1) [16] func-
tion in maturation of L cells. While in exocrine cells, p48 is
required for cell lineage [17].
Activin A, a member of transforming growth factor L
(TGFL) superfamily, has many physiological and develop-
mental functions such as stimulation of follicle stimulating
hormone production in pituitary [18,19], craniofacial develop-
ment [20], and promotion of erythrocyte di¡erentiation [21].
In pancreas, activin A increases insulin content in the rat L cell
line INS-1 [22] and induces the rat pancreatic exocrine acinar-
derived cell line AR42J to produce insulin when treated in
combination with hepatocyte growth factor (HGF) or beta-
cellulin [23,24].
To gain insight into the mechanism of activin function in
pancreatic L cells, the e¡ect of activin on gene expression of
transcription factors was investigated. Activin A was indicated
to increase gene expression of the PAX4, which is one of the
most crucial determinants for L cell di¡erentiation [13], and
the action of activin A was shown to be mediated, at least in
part, by the type IB activin receptor, ALK4. Furthermore, the
author found unique properties of PAX4 and its isoform to-
ward human insulin promoter (HIP) as transcriptional activa-
tors and repressors depending upon their expression levels.
2. Materials and methods
2.1. Materials, cell culture, and isolation of transfectants stably
expressing constitutively active type IB activin receptor ALK4
(Thr206Asp)
Human TGFL1 was obtained from Sigma, and human activin A
was purchased from Austral Biologicals or provided by Dr. Y. Eto
(Ajinomoto). Murine insulin producing NIT1 [25] cells were pur-
chased from ATCC and cultured in Ham’s F12 medium containing
14% fetal calf serum (FCS). Stable NIT1 transfectants expressing
constitutively active type IB activin receptor, ALK4 (T206D) [26],
were isolated by transfection with human ALK4 (T206D) encoding
the gene harbored in pcDNA3 vector (Invitrogen), followed by selec-
tion for G418 resistance. The vector was a gift from Dr. K. Miyazono
(The Cancer Institute) with the permission of Dr. C.H. Heldin (Lud-
wig Institute for Cancer Research). INS-1E L cells [27] were provided
by Dr. C.B. Wollheim (University of Geneva, Switzerland) and cul-
tured in RPMI 1640 medium supplemented with 25 mM HEPES, 5%
FCS, 1 mM pyruvate, and 50 WM 2-mercaptoethanol.
2.2. Measurement of gene expression level
Total RNA was extracted from NIT1 and INS-1E cells using Iso-
gen reagents (Nippon gene); genomic DNA contaminated was re-
moved by DNase I digestion. The resulting RNA was converted
into ¢rst-stranded cDNA using an Advantage-for-RT-PCR kit (Clon-
tech). The gene expression levels of Pax4, insulin, Pdx-1, BETA2,
glyceraldehyde-3-phosphate dehydrogenase (G3PDH), and TFIIDd
(TBP) were determined by real time quantitative PCR analysis using
a PRISM1 7700 Sequence Detection system (Perkin-Elmer Applied
Biosystems) under conditions the supplier recommended [28]; brie£y,
the system consists of cDNA fragment ampli¢cation and £uorescence
detection. The nucleotide sequences of forward and reverse primers
and Taqman probes for each gene are summarized in Table 1. Taq-
man probes were labelled at the 5P end with FAM (6-carboxy-£uo-
rescein) for £uorescence and at 3P end with TAMRA (6-carboxy-tet-
ramethyl-rhodamine) for quenching. The expression level of each gene
was normalized to that of G3PDH in Figs. 1 and 2A and to that of
TFIIDd in Fig. 2C since G3PDH expression levels seemed to vary
among the clones for the latter case.
2.3. Transient transfection
Transient transfection experiments shown in Fig. 2A were carried
out using lipofectamine (LF) 2000 reagent (Gibco BRL) in 6-well
plates containing 2U106 NIT1 cells per well. DNA solution composed
of 12 Wl LF 2000 reagent, 300 Wl OPTI-MEM and 6 Wg of vector
plasmids was added to each well, in which cells were already plated
and grown in 1.4 ml medium. Experiments shown in Figs. 2B and 3
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were performed using LF reagent (Gibco BRL) in 24-well plates con-
taining either 4U105 wild type (WT) NIT1 or 2U105 ALK4 (T206D)
expressing clone lines of NIT1 per well. The cell numbers of the clone
lines are fewer than that of WT because cell size of clone lines were
larger than that of WT. Transfection was performed using 380 Wl
FCS-free OPTI-MEM medium with 6.3 Wl of LF reagent and an
appropriate amount of plasmids (see ¢gure legends) toward each
well, then the medium was replaced with Ham’s F12 supplemented
with FCS 6 h after transfection. Luciferase activity was measured 42 h
(Fig. 3) or 24 h (Fig. 2B) after medium replacement using an ML-
3000B luminometer (Dynatech). The plasmid harboring Xenopus
FAST-1 [29] was a gift from Dr. M. Whitman (Harvard University).
The reporter vector pALUC5 was generated by inserting ¢ve in line
repeats of activin response element (ARE) [30] upstream of the TATA
box in the pGV-B2 luciferase vector (Tokyo Ink). The HIP reporter
vector pIns-Luc380 was constructed by inserting the 3342 to +37
region of the human insulin gene, in which +1 denotes putative cap-
ping site [31,32], directly upstream of the luciferase gene of pGV-B2
without TATA box. The expression vectors of PAX4 and its isoform
were constructed by cloning PCR ampli¢ed fragments encoding each
gene into pcDNA3.1 vector.
2.4. Measurement of insulin content
NIT1 cells plated in 24-well plates, containing either 4U105 WT or
2U105 clones per well, were lysed in 0.15 ml of bu¡er containing
20 mM Tris^HCl (pH 7.5), 1% Triton X-100, 150 mM NaCl, 5 mM
EDTA, 2 mM Na3VO4, 10 mM NaF, 1 mM PMSF and Complete1
reagent (Boehringer). These lysates were diluted 150-fold and sub-
jected to insulin content measurement using Phadeseph insulin RIA
kit (Pharmacia-Upjohn). The data were normalized to total protein
level, which was determined by a protein assay kit (Bio-Rad).
3. Results and discussion
3.1. Activin A increases Pax4 gene expression
When NIT1 cells were treated with activin, no change in
homeobox transcription factor PDX-1 or basic helix-loop-he-
lix transcription factor BETA2 transcript levels were ob-
served. However, transcript levels of PAX4, which contains
both a paired domain and a homeodomain in its molecule and
whose knockout prevents L cell development [13], did increase
although the direct involvement of PAX4 in insulin gene tran-
scription has not been shown (Fig. 1A). Activin dose depend-
ently and speci¢cally elicited this response; both bone mor-
phogenetic protein (BMP) 2 and TGFL, other members of the
TGFL superfamily, had either no e¡ect or decreased Pax4
expression (Fig. 1B,C). In addition, only activin also increased
slightly the gene expression of insulin (Fig. 1C).
Next, INS-1E cells were treated with activin A to investi-
gate whether the e¡ect of activin is only applicable to NIT1
cells or universally extended to other pancreatic L cell lines.
Fig. 1D indicates that though no signi¢cant di¡erence was
seen for insulin expression, expression of the Pax4 was dra-
matically induced. This activin e¡ect on Pax4 gene expression
is also reported for exocrine acinar AR42J cells when treated
with HGF together [33]. Therefore, the e¡ect of Pax4 induc-
tion by activin A seemed to be universal in insulin-producing
cell lines.
3.2. The e¡ect of activin A is mediated through its receptor
In environment with high Ca2 concentrations, activin A
promotes insulin secretion from L cells. However, this e¡ect
seems not to be mediated by the translation via activin recep-
Table 1
Nucleotide sequences of primers and Taqman probes used for real time quantitative PCR analysis using a PRISM1 7700 Sequence Detection
system
Genes Forward primers Taqman probes Reverse primers
mPax4 GCCTGGGAGATCCAACACCA AGAGCTTGCACTGGCACTGGACTCAACTCAGA GGGAAGAACTGGAGCCA
Insulin ATGGCCCTGTGGATGCGCTTC TCTACACACCCATGTCCCGCC TCAGTTGCAGTAGTTCTCCAG
mPdx-1 CCACCCAGCGCCTAA AGTACTACGCGGCCACACAGCTCTA GAATGCGCACGGGTC
mBETA2 AGCCCCCTAACTGACTGCA CAGCCCTTCCTTTGACGGACCC AGGCATAATTTTTTTCAAACTCG
mG3PDH AAAGTGGAGATTGTTGCCAT CATGTTCCAGTATGACTCCACTCACG TTGACTGTGCCGTTGAATT
mTFIIDd TCTTTAGTCCAATGATGCCTT CCACAGCCTATTCAGAACACCAACAG GGTTGCTGAGATGTTGATTG
rPax4 CTTTTTGCCT GGGAGATCCA CGCCAGCTTTGTGCTGAAGGGC GGAGCCTTGT CCTGGGTACA
rG3PDH AAGCAGGCGGCCGAG TGGGCTACACTGAGGACCAGGTTGTC ATCAAAGGTGGAAGAATGGGA
Distinctions of mouse and rat for each gene are represented by m and r, respectively, at heads of gene names. Primer sets for insulin were com-
monly used toward mouse and rat ones.
Fig. 1. Pax4 gene induction following activin treatment in NIT1
(A^C) and INS-1E (D). A: The expression levels of pancreatic L
cell speci¢c transcription factors (Pdx1, BETA2, Pax4) in NIT1 cells
treated with (F) or without (E) 2 nM activin A for 12 h. B: Dose
dependency of the e¡ect of activin on Pax4 expression after 24 h
treatment. C: The expression levels of insulin and Pax4 in cells
treated with 2 nM of human BMP 2 (o), TGFL1 (E),= activin (F),
or control (nothing) (E) for 24 h. D: The expression levels of insu-
lin and Pax4 in INS-1E cells treated with 2 nM of human activin
(F), or control (nothing) (E) for 24 h. The data are normalized to
the expression level of G3PDH, and expressed as relative level to
the no-treatment level as mean þ S.D. (n = 4). *, P6 0.05; **,
P6 0.01; ***, P6 0.001 (Student’s t-test for A, D and Dunnett for
B, C).
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tor since insulin secretion occurs very quickly [34]. To test
whether activin-induced Pax4 expression is mediated by acti-
vin receptor, ¢rst, constitutively active form type IB activin
receptor, ALK4 (T206D) [26] was transiently expressed in
NIT1 cells and the responses were compared with activin
treatment. Fig. 2A demonstrates ALK4 (T206D) expression
induced Pax4 gene expression by 67% intensity of activin
treatment. Since transfection e⁄ciency using LF 2000 reagent
was estimated to be about 50% when monitored by green
£uorescent protein after transfection with its expression vector
(data not shown), the e¡ect of ALK4 (T206D) transient ex-
pression on Pax4 induction seemed to be adequate.
Next, ALK4 (T206D) was stably expressed in NIT1 cells.
Four distinct clones (#4, #14, #28, and #39) were obtained.
The intracellular activin signal activities of these clones were
estimated taking advantage of the ARE reporter system in
combination with the Xenopus FAST-1 transcription factor
[29,30]. Clone #4 exhibited nearly the same strength as 2 nM
activin stimulus, and other clones elicited moderate activities
(Fig. 2B). PAX4 transcript levels of all these clones were in-
creased as activin-treatment (Fig. 2C). The results of these
transient and stable transfection experiments exhibited Pax4
expression is mediated, at least in part, by the type IB activin
receptor.
Activin treatment slightly (10%) increased the insulin con-
tent of WT cells as reported for INS-1 cells [22]. Similarly but
extremely, insulin contents of these stably ALK4 (T206D)
expressing clones were augmented (Fig. 2D). From the mor-
phological point of view, #4 and #39 were markedly, #28 was
moderately, and #14 was slightly hypertrophic (larger cell
size), respectively, compared with WT NIT1 cells (Fig. 2E).
In terms of cell morphology and insulin content, it is note-
Fig. 2. The e¡ect of transient (A) and stable (B^E) expression of ALK4 (T206D) in NIT1 cells. A: NIT1 cells were transiently transfected with
control vector pcDNA3.1 (Invitrogen) for two groups or ALK4 (T206D) expression vector derived from pcDNA3. Activin A was supplemented
as 2 nM to one group of control 6 h after transfection, and the Pax4 gene expression of each group was investigated 30 h after transfection.
B: Intracellular activin signal intensities of WT, activin-treated WT (Act), and individual stable clone lines estimated by the ARE-luciferase sys-
tem. Cells in 24-well dishes were transfected with 0.63 Wg of pALUC5 and 0.063 Wg of FAST-1 vector using 6.3 Wl of LF reagent per well.
C: The expression level of Pax4. D: Insulin content. E: Photos of WT and stable clones (#4, #14, #28, #39) just after passage (top) on hemo-
cytometer or cultured for 18 h after passage (bottom). The data are normalized to the G3PDH gene expression level for A or to the TFIIDd
gene expression level for C, and to the total protein level for B, D, and represented as relative value to WT as the mean þ S.D. (n = 4).
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worthy to refer that not only transgenic mice expressing dom-
inant negative type II activin receptor but also those express-
ing constitutively active ALK4 (T206D) exhibit hypoplasia of
pancreatic islets (small area) and a lower insulin content [35].
Fig. 2D,E seems to be consistent with the results of the former
case of transgenic mice, and not with the latter case. These
results seem to imply that appropriate strength of activin sig-
nal is required for the maintenance of L cell function and
signal intensity might a¡ect the size of L cells.
3.3. PAX4 and its isoform a¡ect HIP by dual modes
To investigate the role of PAX4 in insulin gene expression,
a HIP reporter system was utilized in NIT1 cells. Previous
reports indicate that there are three and four splicing isoforms
of PAX4 in mouse [36] and rat [37], respectively. The intact
PAX4 isoform is most abundant and the levels of two deleted
isoforms, PAX4 v(Gly-239^Pro-251) and PAX4 v(Phe-278^
Ser-314) are only one-tenth that of the intact form in MIN6
murine L cells [36]. In NIT1 cells intact PAX4 was also the
major isoform, and PAX4 v(G239^P251) was expressed at
one-third the intact isoform amount as estimated by RT-
PCR, but the level of Pax4 v(F278^S314) was faint or invis-
ible. And activin treatment to NIT1 seemed to increase pro-
portionally both intact PAX4 and PAX4 v(G239^P251) iso-
form (data not shown).
The cDNAs of these two proteins were cloned to expression
vectors and their e¡ects on the HIP were analyzed. At low
levels, both proteins exhibited slight (5^7%) transactivation
activities. However, at higher doses both proteins suppressed
transcription (Fig. 3), implying their dual roles as activators
and as repressors for insulin gene expression depending upon
their intracellular levels, though the e¡ect might not be so
critical. These dual modes functions of PAX4 are similar to
the case of PDX-1 for insulin expression found in the rat
RIN38 L cell line [38].
Recently, PAX4 is regarded to work in L cells as a repres-
sor, especially competing against PAX6, which is associated
with pancreatic K cell function [14], but does have transacti-
vation function when expressed by a C-terminal domain form
[39^42]. The present results matched these ones. It is intrigu-
ing that repression activity was attenuated in the PAX4
v(G239^P251) isoform compared with the intact one, suggest-
ing G239^P251 domain, which is just adjacent to the homeo-
box domain and not found in PAX6 as an activator molecule
when the amino acid sequence of PAX6 is aligned with that of
PAX4 [35], might be crucial for repression activity by dint of
unknown mechanisms such as a¡ecting whole conformation
of the PAX4 molecule and/or interacting with unknown fac-
tors so as to reduce activator activity.
PAX4 is shown to bind directly on rat insulin-1 promoter
[40], however, putative paired domain binding motifs not al-
ways seem to be the same (G(A/C)ANTCANGCGTG or
GNN(G/T)T(C/G)A(T/A)GCGTG or ANNTTCACGC) [39^
41], therefore, it remains to be elucidated whether PAX4 di-
rectly binds to its cognate region on the HIP.
3.4. Conclusions
The results of the present study indicated that (i) Pax4 gene
expression is induced by activin A and the signal is mediated
through its receptor, ALK4, (ii) PAX4 and its isoform might
positively and negatively regulate the HIP activity depending
on their expression levels and they showed di¡erence in re-
pression activities. Consequently, these ¢ndings con¢rm the
signi¢cance of activin signal transduction in pancreatic L cell
function. Activin signal is known to be mediated by transcrip-
tion factors termed Smad2/3 and Smad4 [43^47], and Smad2
is involved in the transdi¡erentiation of AR42J cells into in-
sulin producing ones induced by activin A plus HGF [48].
Taken together, modulators of activin signal transduction
might be promising therapeutic targets toward pancreatic L
cell dysfunction caused by diabetes mellitus.
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